肝细胞肝癌中p15基因产物的表达及其意义
被引量:3
Expression and significance of p15 gene in the human hepatocellular carcinoma
摘要
用免疫组织化学方法 (SABC法 )检测p15基因在 5 3例肝细胞肝癌 (HCC )标本中的表达。p15基因阳性表达率为 64 .2 % ( 3 4/5 3 )。病理I ,II级p15阳性率明显高于III级 (均为P <0 .0 5 ) ;临床分期T1 ,T2 期p15阳性率均明显高于T3期 (均为P <0 .0 5 )与T4 期 (均为P <0 .0 1)。提示p15基因的异常表达在HCC的发生、发展中可能起重要作用 ;p15基因表达可以作为病程、预后判断的候选检测指标 ,对HCC的基因治疗有潜在的价值和意义。
出处
《中国普通外科杂志》
CAS
CSCD
2004年第7期540-542,共3页
China Journal of General Surgery
参考文献14
-
1Bonilla F,Orlow 1,Cordon CC. Mutational study of p16 CDKN2/MTS1/ INK4A and p57KIP2 genes in hepatocellular carcinoma[ J]. Int J Oncol, 1998,12(3) :583 -588.
-
2Santoni RE, Jensen MR, Factor VM, et al. Acceleration of c - myc - in- duced hepatocarcinogensis by Co - expression of transforming growth factor (TGF) -alpha in transgenic mice is associated with TGF- betal signaling disruption [J]. Am J Pathol, 1999,154 (6): 1693 - 1700.
-
3Jin M,Piao Z, Kim NG, et al. p16 is a major inactivation target in hepatocellular carcinoma [J]. Cancer,2000,89 (1) :60 - 68.
-
4Bostrom J, Meyer PB,Wolter M, et al. Alterations of the tumor suppressor genes CDKN2A(pl6 (INK4a)), p14 (ARF), CDKN2B (p15(INK4b) ), and CDKN2C ( p18 ( INK4c ) ) in atypical and anaplastic meningiomas [ J ]. AM J Pathol, 2001,159 ( 2 ): 661 - 669.
-
5Matsuzaki K, Date M, Furukawa F, et al. Regulatory mechanisms for transforming growth factor beta as an autoerine inhibitor in human hepatocellular carcinoma:implications for roles of smads in its growth [J].Hepatology ,2000,32 ( 2 ) :218 - 227.
-
6Biden K,Young J,Buttenshaw R, et al. Frequent of mutation and deletion of the tumor suppressor gene CDKN2A ( MTSI/pl 6 ) in hepatocellular carcinoma from an Australian population[ J ]. Hepatology, 1997,25(3) :595 -597.
-
7Lin YW, Chen CH, Huang GT, et al. Infrequent mutations and no methylation of CDKN2A ( P16/MTSI ) and CDKN2B ( P15/MTS2 ) in hepatocellular carcinoma in Taiwan [J]. Eur Cancer, 1998,34 ( 11 ):1789 - 1795.
-
8Liew CT, Li HM,Lo KW, et al. Frequent allelic loss on chromosome 9 in hepatocellular carcinoma [J]. Int J Cancer, 1999,81 ( 3 ) :319 - 324.
-
9Baur AS,Shaw P,Burri N, et al. Frequent methylation silencing of p15 (INK4b) (MTS2) and p16 (INK4a) ( MTS1 ) in B - cell and T - celllymphomas[J]. BLIID,1999,94(5 ) :1773 - 1781.
-
10Dano L,Guily MN,Muleris M, et al. CGH analysis of radon -inducedrat lung tumors indicates similarities with human lung eancers [J].Genes Chromosomes Cancer,2000,29(1) :1 -8.
同被引文献38
-
1邓伟,梁力建.血管生成素和VEGF在人肝细胞癌血管生成作用机制的研究[J].中国普通外科杂志,2005,14(6):436-440. 被引量:9
-
2Sun X,Kanwar JR,Leung E,et al.Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression[J].Cancer Gene Ther,2001,8(10):719 -727.
-
3Hanahan D,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353 -364.
-
4Gohji K,Katsuoka Y,Okamoto M,et al.[Human heparanase:roles in invasion and metastasis of cancer[J].Hinyokika Kiyo,2000,46(10):757 -762.
-
5Araya M,Terashima M,Takagane A,et al.Microvessel count predicts metastasis and prognosis in patients with gastric cancer[J].J Surg Oncol,1997,65(4):232 -236.
-
6Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(21):1182 -1186.
-
7Ferrara N,Houck K,Jakeman L,et al.Molecular and biological properties of the vascular endothelial growth factor family of proteins[J].Endocr Rev,1992,13(1):18 -32.
-
8Blancher C,Harris AL.The molecular basis of the hypoxia response pathway:tumour hypoxia as a therapy target[J].Cancer Metastasis Rev,1998.17(2):187-194.
-
9Ding I,Sun JZ,Fenton B,et al.Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4murine mammary carcinomas[J].Cancer Res,2001,61 (2):526 -531.
-
10Zhong H,Agani F,Baccala AA,et al.Increased expression of hypoxia inducible factor-1 alpha in rat and human prostate cancer[J].Cancer Res,1998,58(23):5280 -5284.
引证文献3
-
1陈罡,罗殿中,李萍,郭芳.原发性肝细胞癌、癌旁及肝硬化组织中CD3+细胞的研究[J].中国普通外科杂志,2005,14(2):142-145. 被引量:3
-
2董典宁,孙平,智绪亭,寿楠海,孙学英.反义HIF-1α基因治疗人肝癌裸鼠移植瘤的实验研究[J].中国普通外科杂志,2006,15(7):520-524. 被引量:6
-
3董典宁,孙平,智绪亭,刘凤军,孙学英,寿楠海.Angiostatin基因联合反义HIF-1α基因治疗人肝癌裸鼠移植瘤的实验研究[J].中华肝胆外科杂志,2007,13(6):410-413.
二级引证文献9
-
1张波,孔宪炳.低氧诱导因子-1与肝细胞癌[J].临床外科杂志,2007,15(3):202-204. 被引量:2
-
2陈淑勤,汪晓军,高凌云,袁芳平.原发性肝细胞癌组织中T、B淋巴细胞浸润的研究[J].实用肿瘤学杂志,2007,21(4):328-329.
-
3王殿栋,何涛.HIF-1和VEGF在肿瘤血管形成中的研究进展[J].包头医学院学报,2007,23(6):656-658. 被引量:1
-
4罗仕华,郑传胜.经介入途径基因治疗肝癌的回顾与展望[J].临床放射学杂志,2008,27(2):282-285. 被引量:3
-
5徐文雄,樊海宁,秦伟.SIRNA表达载体与阳离子脂质体复合物转染HEPG-2细胞的实验研究[J].当代医学,2008,14(8):45-47.
-
6周家鹏,杨竹林,周建平,刘栋才,舒国顺,袁联文,任峰.胃良恶性病变组织中VHL和HIF-1α及其mRNA表达与MV计数的关系[J].中国普通外科杂志,2009,18(4):334-339.
-
7刘江惠,李建涛,贺宇彤,戴晓晖,郭建文,左连富.食管癌贲门癌患者T淋巴细胞、NK细胞免疫功能检测及意义[J].中国老年学杂志,2010,30(6):729-731. 被引量:13
-
8郑晓彬,林丽平,陈强,郑雄伟,力超,叶韵斌.原发性肝细胞癌组织免疫微环境的分析[J].中国肿瘤生物治疗杂志,2010,17(4):450-454.
-
9贾淑薇,董蕾,贾辉,马丽,靳耀峰.HIF-1α和VEGF-c在胃癌组织中的表达及临床意义研究[J].现代生物医学进展,2013,13(32):6351-6354. 被引量:4
-
1李华,王育斌,张端莲,陕声国,余瑛,杨勇.皮肤血管瘤组织中p15基因产物表达及意义[J].数理医药学杂志,2004,17(6):491-492. 被引量:1
-
2朱振双,陈伟庆,房殿亮,张杨.p15基因对人肝癌HepG2顺铂耐药细胞周期和耐药性的影响研究[J].中国药房,2012,23(41):3888-3890.
-
3李霞.宫颈癌组织中p15基因表达及其生物学意义[J].肿瘤防治研究,2000,27(2):99-100.
-
4崔言刚.肿瘤抑制基因p15与肺癌[J].国外医学(呼吸系统分册),2000,20(4):188-189.
-
5彭惠,杨光华,郭立新,步宏,胥健敏,张世羽.软组织平滑肌肉瘤中肿瘤抑制基因p15、p16的表达[J].临床与实验病理学杂志,2001,17(2):133-135. 被引量:1
-
6蒋俊煌,严俊,林素霞,王光武,陈国勇,陈国章,沈建箴.MSP检测p15基因甲基化在儿童急性白血病微小残留病灶诊断中的价值[J].中国小儿血液,2002,7(1):1-3. 被引量:1
-
7程越,张长松,郭献灵,卫立辛.肝细胞癌多基因甲基化研究[J].分子影像学杂志,2016,39(1):33-36. 被引量:2
-
8李霞.宫颈癌组织中p16和p15基因产物表达及其生物学意义[J].肿瘤防治杂志,2000,7(2):146-147.
-
9张飞燕,李芳,王帅,何芳.P16、P15及PCNA在宫颈癌中的表达及临床病理意义[J].中国医药导刊,2013,15(S1):182-183.
-
10陈龙,陈洁平.c-myc对肿瘤细胞生长抑制基因的转录调控[J].中华肿瘤防治杂志,2006,13(22):1752-1754. 被引量:14